Breast cancer prevention with bisphosphonates and aromatase inhibitors: a systematic review

Background and objectives:IARC1 in 2018 claims that the world faces more than 18million new cases of cancer, of which 9million will lead to death. The average incidence of cancer in Iran is similar to the world(world:182per100,000people, Iran:158per100,000people). Breast cancer has greatest incidence in the world(11.6%) and in Iran(12.5%). Bisphosphonates and aromatase inhibitors(AIs) are two class of cheap drugs that prevent the loss of bone density. Studying the effects of bisphosphonates and AIs on breast cancer prevention is main goal. Search Method: This essay are a systematic review of English articles published in PubMed, Research gate and Lancet since 2010. Being up to date, matching with keywords and accessing the full text were incoming metrics. Findings: Compared to Herceptin and Tamoxifen, AIs were able to reduce the likelihood of the cancer recurring by about a third over 5years. AIs also reduced the risk of dying by about15% over the10 years. When AIs were compared to no treatment at all, the reduced risk of dying shot up to40%. Bisphosphonates could reduce secondary tumors growing in the bone by17%. Researchers found that 2-5years with bisphosphonates reduced recurrence of cancer in the bone by28% and cut death rates by18% over the course of a decade. There are, however, some side effects to taking AIs. AIs can cause a reduction in bone density so two types of drug should be used together. Conclusions: These results show bisphosphonates reduce the chance of breast cancer returning in the bones. Aromatase inhibitors block the body’s ability to make estrogen, which can fuel the growth of breast cancer. These cheap treatments should be considered for routine use in the treatment of early breast cancer. Further research is still important to how to give these drugs in combination with each other.

کلیدواژه ها:

aromatase inhibitors ، bisphosphonates ، breast cancer prevention ، bone